Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue (2016 - 2020)
Historic Non-Current Deffered Revenue for Agios Pharmaceuticals (AGIO) over the last 9 years, with Q2 2020 value amounting to $491000.0.
- Agios Pharmaceuticals' Non-Current Deffered Revenue fell 9904.87% to $491000.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $491000.0, marking a year-over-year decrease of 9904.87%. This contributed to the annual value of $50.6 million for FY2019, which is 1543.08% down from last year.
- Latest data reveals that Agios Pharmaceuticals reported Non-Current Deffered Revenue of $491000.0 as of Q2 2020, which was down 9904.87% from $571000.0 recorded in Q1 2020.
- In the past 5 years, Agios Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $183.5 million in Q2 2016 and a low of $491000.0 during Q2 2020
- For the 5-year period, Agios Pharmaceuticals' Non-Current Deffered Revenue averaged around $87.2 million, with its median value being $69.4 million (2018).
- Per our database at Business Quant, Agios Pharmaceuticals' Non-Current Deffered Revenue surged by 107420.51% in 2016 and then tumbled by 9904.87% in 2020.
- Agios Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $154.3 million in 2016, then fell by 18.47% to $125.8 million in 2017, then tumbled by 52.46% to $59.8 million in 2018, then dropped by 15.43% to $50.6 million in 2019, then crashed by 99.03% to $491000.0 in 2020.
- Its Non-Current Deffered Revenue stands at $491000.0 for Q2 2020, versus $571000.0 for Q1 2020 and $50.6 million for Q4 2019.